Treatment options for patients with advanced NSCLC without EGFR or ALK mutations, such as platinum-based regimens, were limited to conventional chemotherapy before the emergence of immunotherapy, which has been reimbursed in South Korea since August 2017. This evidence concerns the gene EGFR and non-small cell lung carcinoma.